EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid

Guirong Liang, Hua Qian, Chao Sun, Hanmei Zhang, Zhiliang Li, Suo Li, Ke Jing, Chenjing Zhao, Yuan Wang, Ruiyu Xiang, Xiaoguang Li, Suying Feng

Anais Brasileiros de Dermatologia · 2025

DOI: 10.1016/j.abd.2024.04.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Guirong Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Antibodies, Monoclonal, Humanized, Adrenal Cortex Hormones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conventional systemic corticosteroid therapy for bullous pemphigoid (BP) has been challenged due to severe adverse events. Dupilumab has emerged as an alternative therapeutical option of BP patients.

Objectives

To evaluate the efficacy of dupilumab monotherapy and the combination with medium/low-dose corticosteroids for BP treatment.

Methods

Thirteen, twenty-four and thirty-two BP patients treated with Dupilumab monotherapy (Dupi group), dupilumab combined with corticosteroids (Dupi + CS group), and corticosteroid monotherapy (CS group), respectively, were retrospectively analyzed for various clinical and laboratory parameters.

Results

In the Dupi group, the total Bullous Pemphigoid Disease Area Index (BPDAI) Total, Erosion/Blister, Urticaria/Erythema and Itching NRS scores were all reduced significantly after 2-4 weeks of treatment, but the BPDAI Mucosal Score was not changed significantly at the end of the overextended time of treatment. All the above clinical parameters and many laboratory parameters (including the serum anti-BP180 autoantibodies [IgG] level, blood eosinophil count, and percentage) were significantly reduced in both Dupi + CS and CS groups after treatment, but no statistical differences were found in the reduction rates of these parameters between the two groups. However, the Dupi + CS group had less baseline dose and cumulative dosage of prednisone at the time of disease control, and fewer adverse effects were reported than the CS group. Study limitations: The retrospective design and small clinical sample size of the Dupi group.

Conclusions

For BP patients, dupilumab monotherapy based on the treatment of atopic dermatitis can significantly improve skin lesions and pruritus symptoms but may be ineffective for oral mucosal lesions. The combination of dupilumab and medium/low-dose corticosteroids can achieve the same effect of corticosteroid therapy with superior safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousAntibodies, Monoclonal, HumanizedAdrenal Cortex HormonesHumansMaleRetrospective StudiesFemaleDrug Therapy, CombinationTreatment OutcomeAgedMiddle AgedSeverity of Illness IndexAged, 80 and overAdult

Stichwörter der Autor:innen

CorticosteroidsDermatosis bullosa IgA linealDupilumabPemphigoid, bullousTreatment outcome

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
  • School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, Hunan, China; Department of Laboratory Medicine, Medical College, Dalian University, Dalian, Liaoning, China.
  • Department of Dermatology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
  • School of Public Health and Laboratory Medicine, Hunan University of Medicine, Huaihua, Hunan, China; Department of Laboratory Medicine, Medical College, Dalian University, Dalian, Liaoning, China. Electronic address: l…
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China. Electronic address: fengsy@pumcderm.cams.cn.

Zitieren

APA

Liang, G., Qian, H., Sun, C., Zhang, H., Li, Z., Li, S., Jing, K., Zhao, C., Wang, Y., Xiang, R., Li, X., & Feng, S. (2025). Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.04.012

Vancouver

Liang G, Qian H, Sun C, Zhang H, Li Z, Li S, et al. Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.04.012

BibTeX
@article{Liang2025,
  author = {Liang, Guirong and Qian, Hua and Sun, Chao and Zhang, Hanmei and Li, Zhiliang and Li, Suo and Jing, Ke and Zhao, Chenjing and Wang, Yuan and Xiang, Ruiyu and Li, Xiaoguang and Feng, Suying},
  title = {Dupilumab, corticosteroids and their combination for the treatment of bullous pemphigoid},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2025},
  doi = {10.1016/j.abd.2024.04.012}
}
Kostenlos starten →